Antibe Announces Appointment of Receiver
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“Stay”) under the Companies’ Creditors Arrangement Act (the “CCAA”) at a hearing before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024.
Antibe Announces TSX Delisting Review
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Antibe to Present Otenaproxesul PK/PD Results at Meeting
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Reports Q3 2024 Interim Financial and Operating Results
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Announces Amendment to Warrant Terms